News | June 02, 2021
Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
The company posted net profit of Rs.62.17 crores for the period ended December 31, 2019.
The company posted net loss of Rs. 661.16 crores for the period ended December 31, 2019.
Subscribe To Our Newsletter & Stay Updated
